论文部分内容阅读
目的评价复方鳖甲软肝片联合恩替卡韦治疗乙型肝炎(乙肝)后肝硬化的临床效果。方法 80例乙肝后肝硬化患者随机分成对照组和实验组,各40例。对照组患者给予恩替卡韦治疗,实验组患者在对照组的基础上联合复方鳖甲软肝片治疗。比较两组患者治疗效果及肝功能指标、肝纤维化指标。结果经治疗,实验组临床治疗总有效率85.0%高于对照组的65.0%,差异有统计学意义(P<0.05)。实验组患者治疗后的肝功能指标、肝纤维化指标均显著优于对照组,差异有统计学意义(P<0.05)。结论在对乙肝后肝硬化患者进行治疗时,复方鳖甲软肝片联合恩替卡韦治疗具有比较显著的临床疗效,具有临床应用价值。
Objective To evaluate the clinical effect of Fufang Biejia Ruangan Pian combined with entecavir in treating cirrhosis of liver after Hepatitis B (Hepatitis B). Methods Eighty patients with posthepatitic cirrhosis were randomly divided into control group and experimental group, 40 cases each. Patients in the control group were treated with entecavir. Patients in the experimental group were treated with Fufang Biejia Ruangan Pian on the basis of the control group. Comparison of two groups of patients with treatment and liver function indicators, liver fibrosis indicators. Results After treatment, the total effective rate of clinical trial in experimental group was 85.0% higher than that in control group (65.0%), the difference was statistically significant (P <0.05). The liver function index and liver fibrosis index of the experimental group were significantly better than the control group after treatment, the difference was statistically significant (P <0.05). Conclusion When treating patients with posthepatitic cirrhosis, compound Biejia Ruangan Pian combined with entecavir has obvious clinical curative effect and has clinical value.